H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Cortexyme (NASDAQ:CRTX) Inc on Wednesday, setting a price target of $30, which is approximately 47.99% below the present share price of $57.68.
Fein expects Cortexyme Inc to post earnings per share (EPS) of -$0.74 for the fourth quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Cortexyme, with an average price target of $92.
The analysts price targets range from a high of $150 to a low of $30.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $0 and a net profit of -$21.78 million. The company's market cap is $1.71 billion.
According to TipRanks.com, H.C. Wainwright analyst Andrew Fein is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.3% and a 50.34% success rate.
Cortexyme, Inc. is a biopharmaceutical company, which develops therapeutics based on data supporting a new theory of the cause of Alzheimer's and other neurodegenerative disorders. Its product, COR388, is in clinical trial. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.